Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2024, Alexandria has a total market capitalization of $33.1 billion and an asset base in North America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

Alexandria Real Estate Equities Inc.

An announcement from American Rebel Holdings ( ($AREB) ) is now available. On March 23, 2026, American Rebel Holdings implemented a 1-for-100 rever...

American Rebel Addresses Nasdaq Deficiency With Share Issuance

RBC Capital analyst Luca Issi maintained a Buy rating on Ultragenyx Pharmaceutical on April 7 and set a price target of $35.00. The company’s share...

RBC Capital Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

In a report released today, from National Bank maintained a Buy rating on Aecon Group Inc., with a price target of C$48.00. In addition to National...

National Bank Reaffirms Their Buy Rating on Aecon Group Inc. (ARE)

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, gained 0.43% in pre-ma...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/8/2026

In a report released today, Benjamin Budish from Barclays maintained a Buy rating on Ares Management, with a price target of $127.00. Budish covers...

Barclays Keeps Their Buy Rating on Ares Management (ARES)

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, lost 0.03% in pre-mark...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/7/2026

Bank of America Securities analyst Craig Siegenthaler maintained a Buy rating on Ares Management on April 2 and set a price target of $148.00. Sieg...

Bank of America Securities Reaffirms Their Buy Rating on Ares Management (ARES)

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, closed 0.16% higher on...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/3/2026

Asset manager Blue Owl Capital ($OWL) is facing a sharp increase in investor withdrawals, with roughly $5.4 billion in redemption requests hitting ...

Blue Owl Caps Redemptions after Getting Hit with $5.4B in Withdrawal Requests

Ultragenyx Pharmaceutical ( ($RARE) ) has issued an update. On April 2, 2026, Ultragenyx Pharmaceutical announced that the U.S. Food and Drug Admin...

Ultragenyx BLA for UX111 Accepted for FDA Review

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, lost 0.23% in pre-mark...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/2/2026

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, lost 0.20% in pre-mark...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/1/2026

Alexandria Equities ( ($ARE) ) just unveiled an announcement. On March 31, 2026, Alexandria Real Estate Equities, Inc. filed Articles Supplementary...

Alexandria Equities Adopts Simple Majority Director Removal Standard

Mare Engineering Group SpA ( ($IT:MARE) ) just unveiled an announcement. Mare Group S.p.A. is a digital engineering player listed on Euronext Growt...

Mare Group Doubles Scale in 2025 and Sets Cash‑Generation Focus for 2026

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, gained 0.82% in pre-ma...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 3/31/2026

In a report released yesterday, Devin Dodge from BMO Capital resumed coverage with a Hold rating on Aecon Group Inc. and a price target of C$45.00....

BMO Capital Resumes Coverage with a Hold Rating on Aecon Group Inc. (ARE)

The latest update is out from Ultragenyx Pharmaceutical ( ($RARE) ). On March 30, 2026, Ultragenyx Pharmaceutical announced that the U.S. Food and ...

Ultragenyx Wins FDA IND Clearance for UX016 Therapy

American Rebel Holdings ( ($AREB) ) just unveiled an update. On March 19, 2026, American Rebel entered into a purchase and exchange arrangement tha...

American Rebel Faces Nasdaq Halt Amid Reverse Split Fallout

The latest update is out from Carter Bankshares ( ($CARE) ). On March 26, 2026, Carter Bankshares, Inc. announced that Carter Bank & Trust complete...

Carter Bankshares Sells Nonperforming Justice-Linked Loan Portfolio

Ultragenyx Pharmaceutical, Inc. ($RARE) announced an update on their ongoing clinical study. The phase 3 study “Adeno-Associated Virus Serotype 8-M...

Ultragenyx Nears Key Inflection Point With Completed Phase 3 Gene Therapy Study in GSDIa

Companies in the Real Estate sector have received a lot of coverage today as analysts weigh in on Eastgroup Properties (EGP), Prologis (PLD) and Al...

Analysts Have Conflicting Sentiments on These Real Estate Companies: Eastgroup Properties (EGP), Prologis (PLD) and Alexandria Equities (ARE)

The latest update is out from Various Eateries PLC ADR ( ($GB:VARE) ). Coppa Collective plc, the new name for Various Eateries plc, has rebranded t...

Various Eateries Rebrands as Coppa Collective to Reflect Broader Hospitality Strategy

These are the upcoming stock splits for the week of March 23 to March 27, based on TipRanks’ Stock Splits Calendar. A stock split is a market event...

Upcoming Stock Splits This Week (March 23 to March 27) – Stay Invested

The latest update is out from Various Eateries PLC ADR ( ($GB:VARE) ). Various Eateries PLC reported that all resolutions at its Annual General Mee...

Various Eateries Shareholders Back All AGM Resolutions

TipRanks is home to a collection of the hottest stock market stories for Wenesday.


Morning News Wrap-Up 3/18/26: Today’s Biggest Stock Market Stories!

A class action lawsuit was filed against Ultragenyx Pharmaceutical ($RARE) on February 4, 2026. The federal securities class action alleges that pl...

Ultragenyx Facing Shareholder Lawsuit over Brittle Bone Disease Drug Claims

Ares Management’s ($ARES) shares notched up some gains on Wednesday afternoon after the Bank of America (BofA) ($BAC) called the alternative asset ...

Ares Stock Pops as BofA Flags “Fire Sale Opportunity” amid Private Credit Turmoil

The Arena Group Holdings Inc. (($AREN)) has held its Q4 earnings call. Read on for the main highlights of the call. The Arena Group Holdings Inc. u...

Arena Group Earnings Call Highlights Profitable Turnaround

Roth MKM analyst Mike Niehuser maintained a Buy rating on American Resources on March 13 and set a price target of $5.00. The company’s shares clos...

Roth MKM Keeps Their Buy Rating on American Resources (AREC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immutep (IMMP – Research Report) and Ultragenyx Pharmaceutical (R...

Analysts Conflicted on These Healthcare Names: Immutep (IMMP) and Ultragenyx Pharmaceutical (RARE)

The SPDR S&P 500 ETF Trust ($SPY) was down 0.57% today, March 13, as investors were concerned about the escalating geopolitical conflict and its im...

Why Is the SPY ETF Down Today, 3/13/2026?

Mare Engineering Group SpA ( ($IT:MARE) ) has issued an update. Mare Group S.p.A., an Italian high-tech engineering hub listed on Euronext Growth M...

Mare Group Exits Eles Stake, Redirects Capital to New Growth Plans

Aecon Group Inc. ( ($TSE:ARE) ) just unveiled an update. Aecon Group Inc. has launched a $150 million bought deal offering of 3,822,000 common shar...

Aecon Launches $150 Million Bought Deal Share Offering to Bolster Balance Sheet

The SPDR S&P 500 ETF Trust ($SPY) fell 0.16% today, March 10, as investors reacted to rising Treasury yields, increased volatility, and concerns th...

Current Quarter	$1.74	Next Quarter	$1.63
Current Year	$6.41	Next Year	$6.03
QoQ Growth	-6.3%	YoY Growth	-5.9%
3Y EPS CAGR	-22.3%	Target Price	$58.71
Consensus	Buy	Upside	+33.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARE	$43.99	-1.90%	1.98M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARE	$43.99	-1.9%	1.98M
3
4
5
6

ARE

ARE

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Alexandria Real Estate Equities Inc. Data in Excel

Get Alexandria Real Estate Equities Inc. Data in Excel